Evidence map›Paper›PMID 36843069›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2023

Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.

Takahiro Suyama, Masao Hagihara, Naruaki Matsui, Rie Irie, Yoshiyuki Osamura, Tetsuo Sakai, Shouichi Watanabe, Shintarou Umemoto, Naoki Miyao

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Takahiro SuyamaDepartment of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Naruaki MatsuiDepartment of Pathology, Nippon Koukan Hospital, Kanagawa, Japan.
Rie IrieDepartment of Pathology, Nippon Koukan Hospital, Kanagawa, Japan.
Yoshiyuki OsamuraDepartment of Pathology, Nippon Koukan Hospital, Kanagawa, Japan.
Tetsuo SakaiDepartment of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
Shouichi WatanabeDepartment of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
Shintarou UmemotoDepartment of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
Naoki MiyaoDepartment of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
Nippon Koei (Japan) · JPEiju General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of an 85-year-old male patient diagnosed with human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) that developed from long-lasting pleural effusion (PE) induced by dasatinib treatment for chronic myeloid leukemia (CML). After the onset of this disorder, dasatinib treatment was discontinued and drainage was performed to regress the effusion. The major molecular response (MMR) was thus lost. The patient did not tolerate nilotinib treatment, but bosutinib was successful in restoring MMR. During these clinical courses, the patient suffered from a recurrence of EBL, which was treated with rituximab-based chemotherapy. The PE sample just before the 3

Indexed as

Herpesvirus 8, HumanLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphomaPleural EffusionAged, 80 and overDasatinibHumansMaleProtein Kinase InhibitorsDasatinibProtein Kinase Inhibitorsanti-tumor immunityCD57 positive T celldasatinibHHV8-negative effusion-based lymphomapleural effusion

Identifiers

PMID36843069
PMCPMC10158722
OpenAlexW4322097311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.